730 related articles for article (PubMed ID: 34811893)
1. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
3. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
6. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
Chen XY; Yang F
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
[TBL] [Abstract][Full Text] [Related]
9. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
10. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
15. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
16. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis.
Chen Y; Qin J; Wu Y; Lin Q; Wang J; Zhang W; Liang F; Hui Z; Zhao M; Wang J
Int J Surg; 2023 Sep; 109(9):2794-2807. PubMed ID: 37247009
[TBL] [Abstract][Full Text] [Related]
17. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
Ann Thorac Surg; 2024 Feb; ():. PubMed ID: 38316378
[TBL] [Abstract][Full Text] [Related]
19. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]